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Objective: The prevalence of Type 2 diabetes (T2DM) is growing in Sub-Saharan countries including 
South Africa. This is a concern given its appreciable impact on morbidity, mortality and costs with the 
recent introduction of universal healthcare in South Africa. The purpose of the study was to assess 
the knowledge of patients with T2DM attending a typical community health centres (CHC) regarding 
the management of their disease including risk factors and prevention to guide future initiatives. 
Typically, patients with T2DM in South Africa are managed in ambulatory care including CHCs. 
Method: A quantitative, descriptive cross-sectional study in a CHC. The sample included 217 adults 
with T2DM who have visited a physician as well as the pharmacy. Face-to-face patient exit interviews 
were conducted using a structured questionnaire. Key finding: Females  predominated (65%) , with 
the majority of patients >60 years (38.2%) and more than half from the Indian racial category.  Most 
patients  did not know how their medication controls their diabetes (79.3%) or did not know any of the 
side effects (83.9%) from their medication. Less than half of the patients knew how to take their 
medication, and more than a third of patients indicated that they were not practicing any form of self-
care. Conclusion: The results indicate that these T2DM patients lacked sufficient knowledge regarding 
the management of their disease. Health care managers should consider instigating programmes to 
improve patients’ knowledge about the management of their disease as part of general initiatives 
within South Africa to improve the management of patients with chronic diseases in the public sector. 
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Diabetes mellitus is a growing problem worldwide (1),  with an estimated 16 million adults in Africa 
currently with  diabetes. This figure is likely to grow to 41 million by 2045, enhanced by increasing 
urbanisation and changing lifestyles in Africa (2-4). In South Africa, currently three and a half million 
people have diabetes; however, this figure is likely to be an under-estimate with many patients 
undiagnosed (5). In view of increasing prevalence rates, diabetes has moved from being the fifth 
leading underlying cause of death in 2013 in South Africa to being the second most common cause in 
2016, representing 5.5% of recorded deaths (7). This is no doubt  enhanced by the high prevalence of 
overweight and obesity in South Africa, now at over 50% of the population (8).  
 
Hypertension is also a concern in South Africa with estimates that up to 78% of adults over 50 
currently have hypertension (11, 12). Consequently, the improved management of non-communicable 
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diseases (NCDs), including diabetes, is now a key part of the South African Department of Health’s 
strategy to improve the health of the population in South Africa (13).  
 
Medicines play an important role in the management of NCDs including patients with type-2 diabetes 
(T2DM) along with diet and lifestyle changes. T2DM is the most prevalent type of diabetes affecting 
between 90% and 95% of all patients with diabetes (6, 14, 15), with a considerable impact on 
morbidity, mortality and costs (2, 14, 16, 17). For instance, the prevalence of diabetic retinopathy was 
nearly 30% among patients attending diabetes clinics in Malawi in Africa, a rate four times that of 
Europe (20).  
 
The goal of treatment in patients with T2DM is to keep blood sugar levels at normal or near-normal 
levels to help prevent long term adverse effects such as neuropathy, e.g. neuropathic pain, and 
nephropathy, i.e. kidney damage leading to dialysis (21). However, adherence to prescribed 
medicines is a key concern in patients with T2DM adversely impacting on morbidity and mortality (17, 
22-28).  Adherence rates to medicines among patients with T2DM typically range from 36% and 93% 
(24); with some authors documenting adherence rates as low as 23% among prescribed medicines 
(27). Adherence rates among patients with chronic diseases such as T2DM are typically much lower 
in developing countries than those seen in developed countries (29). This is particularly important in 
patients with T2DM as a combined approach of diet, physical exercise, and adherence to medicines 
helps with glycaemic control to reduce the risk of complications (24). Non-adherence to medicines in 
patients with T2DM is believed to be due in part to inadequate patient knowledge and awareness 
about the importance of adherence, which includes not fully understanding all the drug regimens and 
their implications, alongside issues of forgetfulness and the lack of support mechanisms (24, 26-28, 
36). One way to develop pertinent targeted strategies to address important issues such as how 
patients view and use their medicines is to ascertain patients’ knowledge regarding their medicines 
(12, 26, 37).  
 
Given the rising rates of T2DM in South Africa, we sought as a first step to determine patients’ 
knowledge regarding their medicines for their T2DM among those who attended public community 
health centres (CHCs). CHCs are an important part of ambulatory care in the public healthcare 
system, with currently over 80% of the population in South Africa being treated in public health 
facilities (39). This is particularly important at this time in South Africa following the introduction of 
universal health coverage for all South Africans through the National Health Insurance (NHI) scheme 
(40, 41). Under this initiative, there are ongoing programmes to improve the availability and 
accessibility of medicines to patients with chronic diseases such as T2DM (41), with  regular 6-
monthly clinical monitoring of patients. 
 
We have previously reported our initial findings focusing on patients’ knowledge attending CHCs in 
South Africa about their disease (42). We have taken this further and researched patients’ knowledge 
about the management of their disease, particularly their medicines. We are aware that there have 
been a number of publications looking at key issues surrounding managing patients with T2DM 
including their knowledge and adherence to medicines (36, 43, 44); however, we believe it is still 
important to explore key aspects in South Africa. The findings will be used to help the authorities in 
South Africa further improve their management of patients with T2DM . In addition, help other African 
countries with a growing prevalence of NCDs.    
 
2. Research Methods 
 
2.1 Study design and setting 
The study followed a descriptive, quantitative cross-sectional design. Data were collected by means of 
patient exit interviews using structured questionnaires. The study was conducted at Laudium CHC in 
Pretoria, South Africa. This is a typical CHC in South Africa, 
 
2.2 Population and sample 
The study population included all T2DM patients attending Laudium CHC during the two month study 
period. This clinic treats approximately 500 patients a month with T2DM; consequently, can provide a 
robust basis for assess typical care of patients with T2DM in the public healthcare system in South 
Africa. Convenience sampling was undertaken of adult T2DM patients (≥18 years) who had consulted 
with their medical practitioner as well as collected their medicines from the pharmacy. This resulted in 
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a final sample size of 217 (Figure 1).  Potential participants were given an information leaflet about 
the study, after which they provided written informed consent for participation. 
 
Figure 1 – Patient Flow Chart 
 
 
2.3 Data collection 
The questionnaire was designed in a multiple choice format and consisted of mainly closed-ended 
questions on general knowledge, risk factors, lifestyle modifications including exercise, diet, reducing 
alcohol intake and stopping smoking, current use of medicines and prevention of T2DM. The 
structured questionnaire was developed based on the published literature of validated questionnaires 
regarding patients’ knowledge of their diabetes (45). It was subsequently piloted. Based on the 
findings, amendments were made to the questionnaire including rephrasing certain questions to 
enhance its robustness and validity (Appendix 1). Face-to-face interviews were conducted in a private 
room by a single data collector (AM). The majority of patients visiting the clinic could speak English. 
 4 
 
However, the questionnaire, study information leaflet and consent form were also available in 
Setswana, the other language commonly spoken in this area of South Africa. 
 
2.4 Outcomes 
The outcomes were in terms of patients’ knowledge regarding their disease control and how the 
medicines work, what their prescribed medicines were and the potential side-effects of these. In 
addition, what activities they would take if they experienced any side-effects from their medicines, 
what their knowledge was regarding normal glucose levels and the extent of any self-care practices to 
help control T2DM.  
 
2.5 Data analysis 
Descriptive statistics were used to analyse data. All statistical procedures were performed on SAS, 
Release 9.2 compatible with Microsoft Windows. Responses to open-ended questions were captured 
and manually categorised. Responses to categorical variables were summarised as frequency counts 
and percentages. 
 
2.6 Ethical considerations 
Ethical approval for the study was obtained from the Medunsa Research Ethics Committee of the 
University of Limpopo, now Sefako Makgatho Health Sciences University, prior to the commencement 
of the study (MREC/H/269/2013:PG). Permission to conduct the study at Laudium CHC was obtained 





3.1 Demographic details and duration of diabetes 
Table 1 contains the demographic details of the 217 patients interviewed. 
 
Table 1: Socio-demographic characteristics of the patients (n=217) 
 
Characteristics No. % Characteristics No. % 
Age (year)     Occupational status   
Up to 30 5 2.3 Employed 93 42.9 
31-40 23 10.6 Unemployed 32 14.7 
41-50 49 22.6 Housewife 54 24.9 
51-60 57 26.3 Pensioner 37 17.1 
>60 83 38.2 Student 1 0.5 
Gender      Family history of diabetes 
Female 142 65 Family history  142 65 
Male 75 35 No family history 75 35 
Race      Education 
Black  93 43 No education 36 16 
White 8 4 Primary school completed 108 50 
Coloured 5 2 Secondary school completed 67 31 
Indian 111 51 Tertiary qualification 6 3 
  
 
Two thirds of the patients interviewed indicated that they have been diagnosed for 5 years or more 
with T2DM (67.7%), and that they had been on their anti-diabetic medication for more than 5 years 





Table 2: Duration being diagnosed with diabetes and duration on medication (n=217) 
 
Patients with type-2 diabetes No. % 
Duration being diagnosed     
0-5 years 70 32.3 
5-10 years 77 35.5 
10-15 years 35 16.1 
20+ years 35 16.1 
Duration on medication     
0-5 years 77 35.5 
5-10 years 73 33.6 
10-15 years 36 16.6 
20+ years 31 14.3 
 
3.2 Disease control  
Half of the patients knew whether their diabetes was either controlled (32.7%) or not controlled 
(20.3%); the other half (47.0%) did not know. Almost 80% of patients did not know how their 
medicines control their diabetes. The remainder said their medicines help lower blood sugar (9.2%), 
control high blood sugar levels (6.0%), stabilise glucose levels (4.6%) and control insulin in the body 
(0.5%). One of the patients (0.5%) reported that the medication does not help in controlling diabetes. 
This particular patient also did not know how to take his/her medicines and indeed had an 
uncontrolled blood glucose level. 
 
The findings were similar across the groups in terms of the number of years on anti-diabetic 





Figure 2 - Patients’ knowledge on medicines for the treatment of diabetes by number of years 




3.3 Patient knowledge about the side effects of their medicines  
The majority of patients (182; 83.9%) were not aware of the potential side-effects of the medicines 
they were prescribed (Table 3). Of the 35 patients who knew about potential side-effects that could 
occur, headache and dizziness (57.1%) were the most common ones mentioned. Other common 
side-effects included gastrointestinal disturbances (34.3%) and hypoglycaemia, i.e. low blood sugar 
levels (31.4%). More than half of the 35 patients who were aware of the potential side-effects of their 
medicines indicated that they will immediately consult with their medical practitioner, nurse or clinic if 
these occurred. However, fifteen (42.9%) patients indicated that they do not know what to do if side-
effects occurred (Table 3). 
 
Knowledge, or lack of it, regarding the potential side effects of the medicines prescribed for patients 
with T2DM was again similar among the groups in terms of the number of years on anti-diabetic 





Table 3: Patient knowledge about the side effects of their medicines (n=217), side effects 
experienced (n=35) and management of the side effects (n=35) 
 
Characteristic No. % 
Side effects knowledge (n=217)   
Knowledge about potential side effects 35 16 
No knowledge about side effects 182 84 
 
  
Knowledge of potential side effects (n=35)   
Headache, dizziness 20 57.1 
Gastrointestinal disturbances 12 34.3 
Hypoglycaemia 11 31.4 
Lactic acidosis 2 5.7 
   
Actions to take when potential side effect is 
experienced (n=35)   
Immediately visit doctor/sister/clinic  18 51.4 
Do not know what to do 15 42.9 
Will stop the medication 2 5.7 
 
3.4 Knowledge about medicine use 
Metformin, glibenclamide, and gliclazide were the three medicines most prescribed and used for the 
treatment of patients with T2DM in this CHC (Table 4). The majority of prescribed medicines received 
by the patients were labelled appropriately. The instructions on the labels were compared with 
patients’ responses when asked how they take their medicines. Although patients indicated that they 
were told how to take their medicines, less than half (47.9%) of the 213 patients on metformin, half 
(50%) of the 58 patients on gliclazide, and 2 of the 5 patients on glibenclamide, knew how to take 
them according to the instructions on the label (Table 4).  
 
Table 4: Patient knowledge on the use of medication (n=217) 
 
Patients 
Metformin (n=213) Gliclazide (n=58) Glibenclamide (n=5) 
No. % No. % No. % 
Know how to take their 
medicines 
102 47.9% 29 50% 2 40% 
Told how to take their 
medicines 
199 93.4% 51 87.9% 5 100% 
All medicines labelled 
correctly 
200 93.9% 55 94.8% 5 100% 
 
With regards to missing a dose of their medicines, most patients (67%) said that they would wait for 
the next dose. A minority indicated they will immediately take the missed dose, would take a double 
dose, or did not know what to do (Figure 3). Only six (3%) patients were confident to say that they 









3.5 Blood glucose testing 
Less than half (48.4%) of the patients knew what the normal glucose levels for adults should be 
before a meal. When asked whether they knew what their own glucose level was, 62% of patients 
responded positively. A third (71; 32.7%) knew that their diabetes was controlled; 44 (20.3%) knew it 
was not controlled; and 102 (47.0%) did not know whether it was controlled or not controlled. 
 
Patients’ blood glucose levels are tested at the clinic during monthly visits. Patients were asked how 
often they test their own blood glucose levels themselves. Six (2.8%) patients admitted that they 
never test their blood glucose levels themselves, 59.0% indicated that they test less than once a week 
and 24.9% tested at least once a week. Very few patients reported that they test their blood glucose 
levels either once a day (9.2%) or twice a day (4.1%).   
 
3.6 Self-care practices 
More than a third of the patients (91; 41.9%) indicated that they were not practicing any form of self-
care.  Amongst the 126 patients who indicated they were practicing self-care, exercise (58.7%), 
following a healthy diet (54.8%) and taking their medicines (51.6%) were the most common self-care 





Table 5: Self-care practices (n=126) 
 
Self-care practices No.  % 
Do exercise 74 58.7 
Restrict diet 69 54.8 
Take medicines 65 51.6 
Monitor blood sugar  48 38.1 
No smoking 35 27.8 
Foot care 31 24.6 
Eye examination 27 21.4 
Moderate / no alcohol 11 8.7 




The majority of patients in our study were female, consistent with other African countries (3, 24, 28, 
46, 47). This is perhaps not surprising as in many sub-Saharan Africa countries, including South 
Africa, women are more likely to be obese or overweight than men, and therefore expected to have a 
higher prevalence of type-2 diabetes (8, 48). 
 
Most of the patients in this study were 51 years and older (Table 1). This was probably due to the 
combined effect of a greater number of elderly women than men in most African populations and the 
increasing prevalence of diabetes with age (47). In 2013, it was reported that the majority of 
individuals with diabetes in Africa were under 60 years of age with the highest proportion in people 
aged 40–59 years (47). However, rates are rising among those aged 55 and over(4).  
 
Although most of the patients had been diagnosed 5 to 10 years ago, the majority indicated that they 
were on diabetic medication between 0 and 5 years (Table 2). This is an indication that most patients 
did not commence with anti-diabetic medication as soon as they were diagnosed or they could have 
been prescribed lifestyle modification first. However, most patients (nearly 80%) did not know how 
their medicines control their diabetes (Figure 2), which is similar to other studies among ambulatory 
care patients in lower and middle income countries (44).Our findings are also similar to a study carried 
out among patients with diabetes visiting their general practitioner in the United Kingdom where only 
15% of them knew the correct mechanism of action of their medication (50)  and in India, where 50% 
of diabetic patients in the Warangal region were unaware what diabetes is (51).However, our findings 
are different from patients in Iraq attending a diabetic centre in Hilla city who were seen to have an 
acceptable level of knowledge regarding their disease and activities to keep their disease stable (52), 
and in India where 75.8% of patients attending an ambulatory care clinic knew about the names and 
doses of their diabetes medicines (53). More than 80% of patients in our study were also  unaware of 
the potential side effects of their medicines (Table 3). This is similar to studies undertaken in Ethiopia, 
Lebanon and India among ambulatory care patients in the community or attending specialist clinics in 
hospitals (36, 54, 55). However, higher than another study in India were only 30.1% of patients were 
unaware of the potential side-effects of treatment (53).These findings are a concern as patient 
knowledge regarding their medication is critical not only to prevent medicine-related problems but also 
positively influence treatment success (56). 
 
Encouragingly, most patients said they were told how to take their medicines (Table 4), similar to 
findings in Australia (57).  Most patients (67%) said that they would wait for the next dose if they 
missed a dose (Figure 2), with only a limited number of patients (8%) indicating they would take a 
double dose if they missed a dose. This is similar to the findings of a  study conducted by 
Thungathurthi et al among patients in the Warangal region of India were 7% of patients said they took 
a double dose of medicines when they realised they had missed a dose (51). Of concern is that only 
3% of patients said that they never missed a dose. This  is very low compared to the findings in a 
study carried out in Ethiopia where over 50% of patients never missed a dose (54). However, the 
patients in Ethiopia were attending ambulatory care clinics in a specialist hospital as opposed to a 




In this study, patients who missed their dose of medication did not report it to their healthcare 
provider, which is a concern. Wabe et al. also found that the majority of patients attending ambulatory 
care clinics in a specialist hospital were unaware of the importance of missing doses of their 
medications in terms of reporting this to their physician (54). This is also a concern in view of the 
potential impact of poor adherence on morbidity, mortality and costs, and will be explored further in 
future research projects. There is also a concern that only 38% of patients knew about monitoring 
blood sugar as part of self-care practices (Table 5), However, similar to a study in India where only 
28.1% of patients were regularly monitoring their blood sugar levels (53). Another concern is that 
appropriate foot care is not routinely being practiced among participating patients with only a quarter 
of patients reporting they are taking care of their feet (Table 5). Saleh et al in their study of newly 
diagnosed T2DM patients in ambulatory care also found that 80% of patients were not taking care of 
their feet (58). Appropriate foot care is an important self-care practice in patients with T2DM as it is a 
major cause of morbidity in patients, which leads to lower-extremity amputation in 2% or more of 
diabetes patients increasing costs (59-61). We will be exploring this further in future studies in view of 
the importance of appropriate foot care in these patients. 
 
Wabe et al also reported that knowledge of diabetes self-management practices was higher amongst 
patients attending ambulatory care clinics who never missed a dose and those that have good 
adherence to their medication (54). As a result, highlighting the critical role played by patient 
awareness and practice of diabetes self-management with  improving the care and outcomes of their 
T2DM, which is a key consideration for the future.   
 
Patients must be actively involved in their treatment, and involving them will help increase their 
adherence to treatment (37). Healthcare staff can play an important role improving the self-confidence 
and self-care of patients building on patients being told how to take their medicines (Table 4). This 
includes pharmacists and others improving patients’ knowledge about their disease, as well as 
ensuring they have a satisfactory experience when visiting ambulatory care clinics, to improve future 
medicine use (62-67). Such activities though must take account of the fact that the patient population 
attending CHCs in South Africa (Table 1) typically have no formal education or only primary 
education, similar to other ambulatory care settings in South Africa and other African countries (12, 
24, 28, 68-70). Consequently, story board telling and other similar approaches may be appropriate, 
alongside initiatives such as diaries and counselling involving pharmacists, to improve patient 
knowledge and subsequent medicine use (71, 72). However, we are aware that socio-demographic 
and cultural barriers including issues of exercise, diet and self-monitoring of blood glucose levels, 
have restricted self-care activities in developing countries (73). This also needs to be addressed to 
improve care in this growing group of patients to reduce future morbidity and mortality as well as 
reduce future expenditure. 
 
We acknowledge that there are a number of limitations with this study. Firstly, this study was 
conducted in only one CHC; however, we believe our findings are representational of other CHCs in 
South Africa due to the nature of our population and its location. Secondly, convenience sampling 
was used to enrol patients in the study, which could have introduced sampling bias. Patients could 
also have answered questions incorrectly due to reasons other than poor knowledge, such as being 
nervous when answering the questionnaire. We also did not look at any outcomes of treatment such 
as HbA1c levels, and the extent of any hypoglycaemic episodes, as our focus was purely on patients’ 
knowledge regarding their medicines and current adherence rates. Similarly, we did not investigate 
the effect of duration of diabetes on current regimens.  However in view of the number of patients 
involved and the comprehensive nature of the questionnaire, we believe that the study provides a 
good foundation for developing strategies among public ambulatory care facilities in South Africa to 
improve the management of patients with diabetes. 
 
4. Conclusions and recommendations 
 
Patient knowledge regarding medicines management of T2DM is important as this plays a key role in 
controlling the disease. The results of this study indicate that knowledge among T2DM patients 
attending CHCs in South Africa is not optimal in terms of their medication use and self-care, similar to 
many other countries. This needs to be urgently addressed as our findings fall short of South Africa’s 
vision towards attaining long and healthy lives for all its citizens through the prevention, control and 




We have already seen the government seek to increase access to medicines for all South Africans 
including those with chronic diseases through a variety of initiatives. However, our results highlight the 
need for additional measures to improve the care of patients with T2DM in CHCs else the government 
will not attain its objectives for these patients. Suggested measures include better monitoring of T2DM 
patients, adherence support, education regarding medicine-use including possible side-effects as well 
as improving self-care practices. In addition, prioritising high risk patients and instigating programmes 
for defaulters for follow-up in the CHCs especially for patients with poor adherence to medicines. Most 
importantly in going forward with additional and innovative strategies, future decision-making and 
measures should be underpinned by evidence from operational and practice-based research. Such 
suggestions and their potential implications for improving the care of patients with T2DM in South 
Africa are starting to happen and will be followed up in future research projects. 
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